Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics-Reference-Cited by-同舟云学术

Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics

Published:2020-11 Issue: Volume:49 Page:107243
ISSN:1054-8807
Container-title:Cardiovascular Pathology
language:en
Short-container-title:Cardiovascular Pathology

Author:

Ben-Nun David^ORCID,Buja L. Maximilian^ORCID,Fuentes Francisco

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Pathology and Forensic Medicine

Reference102 articles.

1. Targeting endothelial function to treat heart failure with preserved ejection fraction: the promise of exercise training;Gevaert;Oxid Med Cell Longev,2017

2. Heart failure with preserved ejection fraction in perspective;Pfeffer;Circ Res,2019

3. Heart failure with a normal ejection fraction;Sanderson;Heart,2007

4. The pathophysiology of heart failure with preserved ejection fraction;Borlaug;Nat Rev Cardiol,2014

5. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment;Borlaug;Eur Heart J,2011

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis;Frontiers in Cardiovascular Medicine;2024-08-22

2. miRNAs in Heart Development and Disease;International Journal of Molecular Sciences;2024-01-30

3. Peripheral Blood MicroRNA-21 as a Predictive Biomarker for Heart Failure With Preserved Ejection Fraction in Old Hypertensives;American Journal of Hypertension;2023-11-17

4. Antisense oligonucleotides: a novel Frontier in pharmacological strategy;Frontiers in Pharmacology;2023-11-17

5. Literature Review: Pathophysiology of Heart Failure with Preserved Ejection Fraction;Current Problems in Cardiology;2023-09